Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
prostate cancer
Pharma
Novartis complies with FDA 'flexibility' ask in Pluvicto filing
Novartis didn't use a priority review voucher for Pluvicto's new application upon a request from the FDA, CEO Vas Narasimhan explained.
Angus Liu
Oct 29, 2024 10:51am
After buyouts, Telix unveils new radiopharma spinoff Rhine
Oct 22, 2024 3:05pm
Boston Sci creates docuseries to destigmatize male incontinence
Oct 16, 2024 7:35am
Pfizer targets broad Talzenna label in prostate cancer
Oct 10, 2024 10:18am
J&J's Erleada shows survival edge over Xtandi in real-world study
Oct 2, 2024 2:42pm
Exelixis plots FDA prostate cancer filing despite survival miss
Sep 16, 2024 5:00pm